DoW Breast Cancer, Clinical Research Extension Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Breast Cancer Research Program Clinical Research Extension Award, solicitation number HT942526BCRPCREA2, is issued by the Department of Defense through the Defense Health Agency Contracting Activity. This award focuses on extending data collection, follow-up, and analysis for breast cancer clinical studies to maximize the impact of patient participation and recover knowledge lost from early trial termination or suboptimal data collection. All applications must address the program's overarching challenges or provide a valid justification for an exception. The research team is required to include at least two breast cancer consumer advocates. The funding mechanism supports either a single Principal Investigator or a partnership between an Initiating PI and a Partnering PI. For those choosing the partnering option, the Initiating PI submits the pre-application, but both must submit full applications by the November 18, 2026, deadline to avoid administrative withdrawal.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
• The research team must include two or more breast cancer consumer advocates.
• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
Same awarding agency
